This study is testing whether adding an experimental drug called onvansertib to standard chemotherapy works better for people with advanced colorectal cancer that has spread and has specific genetic changes (KRAS or NRAS mutations). It involves 113 participants who haven't had pr…
Phase: PHASE2 • Sponsor: Cardiff Oncology • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC